Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Subtilisin/kexin type 9 protein convertase and interleukin 1 beta alterations in acute myocardial infarction
1
Department of Cardiology, Faculty of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland
2
Department of Epidemiology, Faculty of Public Health in Bytom, Medical University of Silesia, Katowice, Poland
Corresponding author
Michał Majewski
Katedra i Klinika Kardiologii, Wydział Nauk o Zdrowiu w Katowicach, ul. Ziołowa 47, 40-635 Katowice
Katedra i Klinika Kardiologii, Wydział Nauk o Zdrowiu w Katowicach, ul. Ziołowa 47, 40-635 Katowice
Ann. Acad. Med. Siles. 2025;79:146-154
KEYWORDS
protein convertase subtilisin/kexin type 9interleukin 1 betaacute myocardial infarctiongene expressionperipheral mononuclear blood cells
TOPICS
ABSTRACT
Lipids and inflammation are crucial components in acute myocardial infarction (AMI) pathophysiology. The aim of this study was to assess genetic expression of interleukin 1 beta (IL-1β) and subtilisin/kexin type 9 protein convertase (PCSK9) in AMI patients. 112 AMI patients – 55 with ST-segment elevation myocardial infarction (STEMI) and 57 with non-ST-segment elevation myocardial infarction (NSTEMI) – aged 35 to 92 (average age 65) were enrolled into the study. Control subjects were those with excluded coronary artery disease (CAD; n = 41) and with chronic coronary syndrome (CCS; n = 53). RNA extraction from peripheral blood mononuclear cells (PBMCs) using TRIzol Reagent (Invitrogen) method and genetic expression using quantitative real-time polymerase chain reaction (QRT PCR) method were performed. PCSK9 expression was higher (p = 0.04) and IL-1β lower (p < 0.001) in AMI subjects compared to controls. Higher PCSK9 transcriptional activity was found in more advanced stages of CAD, in male, in cases of increased body weight, decreased left ventricular ejection fraction (LVEF), and high-density lipoprotein (HDL) cholesterol concentration. Higher IL-1β expression was observed in patients with AMI and concomitant hypercholesterolemia. Thorough understanding of IL-1β and PCSK9 biology, key representatives of two basic pathophysiological links underlying myocardial infarction, is of great practical importance. This is particularly important due to currently wide availability of pharmacological intervention within metabolic pathways of these molecules.
FUNDING
This research received no external funding.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES (35)
1.
Virani S.S., Alonso A., Aparicio H.J., Benjamin E.J., Bittencourt M.S., Callaway C.W. et al. Heart Disease and Stroke Statistics – 2021 Update: A Report From the American Heart Association. Circulation 2021; 143(8): e254–e743, doi: 10.1161/CIR.0000000000000950.
2.
Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med. 1999; 340(2): 115–126, doi: 10.1056/NEJM199901143400207.
3.
Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D. et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 2007; 282(25): 18602–18612, doi: 10.1074/jbc.M702027200.
4.
Zheng F., Xing S., Gong Z., Xing Q. NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis. Heart Lung Circ. 2013; 22(9): 746–750, doi: 10.1016/j.hlc.2013.01.012.
5.
Paramel Varghese G., Folkersen L., Strawbridge R.J., Halvorsen B., Yndestad A., Ranheim T. et al. NLRP3 inflammasome expression and activation in human atherosclerosis. J. Am. Heart Assoc. 2016; 5(5): e003031, doi: 10.1161/JAHA.115.003031.
6.
Khovidhunkit W., Kim M.S., Memon R.A., Shigenaga J.K., Moser A.H., Feingold K.R. et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 2004; 45(7): 1169–1196, doi: 10.1194/jlr.R300019-JLR200.
7.
Liao W., Rudling M., Angelin B. Endotoxin suppresses rat hepatic low-density lipoprotein receptor expression. Biochem. J. 1996; 313(Pt 3): 873–878, doi: 10.1042/bj3130873.
8.
Walley K.R., Thain K.R., Russell J.A., Reilly M.P., Meyer N.J., Ferguson J.F. et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci. Transl. Med. 2014; 6(258): 258ra143, doi: 10.1126/scitranslmed.3008782.
9.
Ferri N., Tibolla G., Pirillo A., Cipollone F., Mezzetti A., Pacia S. et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 2012; 220(2): 381–386, doi: 10.1016/j.atherosclerosis.2011.11.026.
10.
Ricci C., Ruscica M., Camera M., Rossetti L., Macchi C., Colciago A. et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci. Rep. 2018; 8(1): 2267, doi: 10.1038/s41598-018-20425-x.
11.
Feingold K.R., Pollock A.S., Moser A.H., Shigenaga J.K., Grunfeld C. Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J. Lipid Res. 1995; 36(7): 1474–1482.
12.
Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020; 41(1): 111–188, doi: 10.1093/eurheartj/ehz455.
13.
Ferri N., Ruscica M. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine 2016; 54(3): 588–601, doi: 10.1007/s12020-016-0939-0.
14.
Almontashiri N.A., Vilmundarson R.O., Ghasemzadeh N., Dandona S., Roberts R., Quyyumi A.A. et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One 2014; 9(9): e106294, doi: 10.1371/journal.pone.0106294.
15.
Feingold K.R., Moser A.H., Shigenaga J.K., Patzek S.M., Grunfeld C. Inflammation stimulates the expression of PCSK9. Biochem. Biophys. Res. Commun. 2008; 374(2): 341–344, doi: 10.1016/j.bbrc.2008.07.023.
16.
Perisic L., Hedin E., Razuvaev A., Lengquist M., Osterholm C., Folkersen L. et al. Profiling of atherosclerotic lesions by gene and tissue microarrays reveals PCSK6 as a novel protease in unstable carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2013; 33(10): 2432–2443, doi: 10.1161/ATVBAHA.113.301743.
17.
Bentzon J.F., Otsuka F., Virmani R., Falk E. Mechanisms of plaque formation and rupture. Circ. Res. 2014; 114(12): 1852–1866, doi: 10.1161/CIRCRESAHA.114.302721.
18.
Parthasarathy S., Quinn M.T., Steinberg D. Is oxidized low density lipoprotein involved in the recruitment and retention of monocyte/macrophages in the artery wall during the initiation of atherosclerosis? Basic Life Sci. 1988; 49: 375–380, doi: 10.1007/978-1-4684-5568-7_58.
19.
Pothineni N.V.K., Karathanasis S.K., Ding Z. Arulandu A., Varughese K.I., Mehta J.L. LOX-1 in atherosclerosis and myocardial ischemia: biology, genetics, and modulation. J. Am. Coll. Cardiol. 2017; 69(22): 2759–2768, doi: 10.1016/j.jacc.2017.04.010.
20.
Ding Z., Liu S., Wang X., Theus S., Deng X., Fan Y. et al. PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovasc. Res. 2018; 114(8): 1145–1153, doi: 10.1093/cvr/cvy079.
21.
Liu A., Frostegård J. PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque. J. Intern. Med. 2018; 284: 193–210, doi: 10.1111/joim.12758.
22.
Ding Z., Wang X., Liu S., Zhou S., Kore R.A., Mu S. et al. NLRP3 inflammasome via IL-1β regulates PCSK9 secretion. Theranostics 2020; 10(16): 7100–7110, doi: 10.7150/thno.45939.
23.
Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature 2010; 464(7293): 1357–1361, doi: 10.1038/nature08938.
24.
Bujak M., Dobaczewski M., Chatila K., Mendoza L.H., Li N., Reddy A. et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am. J. Pathol. 2008; 173(1): 57–67, doi: 10.2353/ajpath.2008.070974.
25.
Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004; 350(14): 1387–1397, doi: 10.1056/NEJMoa032804.
26.
Saxena A., Russo I., Frangogiannis N.G. Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl. Res. 2016; 167(1): 152–166, doi: 10.1016/j.trsl.2015.07.002.
27.
Frangogiannis N.G. Regulation of the inflammatory response in cardiac repair. Circ. Res. 2012; 110(1): 159–173, doi: 10.1161/CIRCRESAHA.111.243162.
28.
Toldo S., Mezzaroma E., Mauro A.G., Salloum F., Van Tassell B.W., Abbate A. The inflammasome in myocardial injury and cardiac remodeling. Antioxid. Redox Signal. 2015; 22(13): 1146–1161, doi: 10.1089/ars.2014.5989.
29.
Zhang Y., Liu J., Li S., Xu R.X., Sun J., Tang Y. et al. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat. BMC Cardiovasc. Disord. 2014; 14: 192, doi: 10.1186/1471-2261-14-192.
30.
Van Tassell B.W., Toldo S., Mezzaroma E., Abbate A. Targeting interleukin-1 in heart disease. Circulation 2013; 128(17): 1910–1923, doi: 10.1161/CIRCULATIONAHA.113.003199.
31.
Hwang M.W., Matsumori A., Furukawa Y., Ono K., Okada M., Iwasaki A. et al. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J. Am. Coll. Cardiol. 2001; 38(5): 1546–1553, doi: 10.1016/s0735-1097(01)01591-1.
32.
Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017; 377(12): 1119–1131, doi: 10.1056/NEJMoa1707914.
33.
Abbate A., Kontos M.C., Abouzaki N.A., Melchior R.D., Thomas C., Van Tassell B.W. et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am. J. Cardiol. 2015; 115(3): 288–292, doi: 10.1016/j.amjcard.2014.11.003.
34.
Antonopoulos A.S., Margaritis M., Lee R., Channon K., Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr. Pharm. Des. 2012; 18(11): 1519–1530, doi: 10.2174/138161212799504803.
35.
Liberale L., Carbone F., Camici G.G., Montecucco F. IL-1β and statin treatment in patients with myocardial infarction and diabetic cardiomyopathy. J. Clin. Med. 2019; 8(11): 1764, doi: 10.3390/jcm8111764.
Share
RELATED ARTICLE
| eISSN: | 1734-025X |
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
